

<b>THE GROUP</b>						
	<b>2010</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>	<b>2006</b>	<b>2005</b>
<b>INCOME STATEMENT</b>						
amounts in €						
Sales (non-biological assets)	57.962.666,37	49.914.365,01	46.186.853,08	45.357.815,00	5.875.600,90	4.495.223,12
Sales (biological assets)	67.433.862,80	62.631.155,94	47.811.588,80	32.872.363,23	29.760.925,95	17.132.405,25
<b>Total Sales</b>	<b>125.396.529,17</b>	<b>112.545.520,95</b>	<b>93.998.441,88</b>	<b>78.230.178,23</b>	<b>35.636.526,85</b>	<b>21.627.628,37</b>
Gross profit (on non-biological assets)	13.480.031,00	10.811.859,75	7.738.851,55	6.492.750,63	801.172,66	390.881,35
Impact from measurement biological assets on fair value	-2.869.149,18	2.619.228,73	14.813.998,66	16.422.768,26		
Cost of developing biological assets	-51.920.249,74	-54.332.189,85	-46.577.522,12	-30.064.958,30		
Gross Operating Profit	26.124.494,88	21.730.054,57	23.786.916,89	25.722.923,82		
Earnings before taxes, financial and investment results	6.281.395,97	12.549.678,19	9.667.244,23	14.707.167,94	7.077.167,21	3.890.955,79
Earnings before tax	406.703,17	6.961.682,75	3.949.850,58	11.632.541,55	5.906.792,11	3.100.966,11
Earnings net of tax	-1.521.898,05	4.574.611,15	2.959.303,54	8.016.492,28	4.440.387,78	2.195.969,48
Allocated among:						
Company shareholders	-1.547.564,34	3.771.605,53	2.672.221,41	8.039.584,09	4.176.639,47	2.171.584,59
Minority interest	25.666,29	803.005,62	287.082,13	-23.091,81	263.748,31	24.384,89
Other total income net of tax	144.510,22	59.000,00				
<b>Basic share of net earnings per share (in €)</b>	<b>-0,0615</b>	<b>0,16</b>	<b>0,11</b>	<b>0,41</b>	<b>0,21</b>	<b>0,11</b>
<b>Dividend proposed per share (in €)</b>						
<b>Earnings before taxes, financial and investment results and total depreciation</b>	<b>8.932.404,43</b>	<b>15.856.531,63</b>	<b>12.731.973,11</b>	<b>16.900.878,81</b>	<b>8.784.447,56</b>	<b>4.938.940,70</b>
<b>THE COMPANY</b>						
	<b>2010</b>	<b>2009</b>	<b>2008</b>	<b>2007</b>	<b>2006</b>	<b>2005</b>
<b>INCOME STATEMENT</b>						
amounts in €						
Sales (non-biological assets)	62.405.555,40	35.397.180,52	28.526.965,28	19.027.033,11	10.975.712,09	5.657.715,72
Sales (biological assets)	51.819.361,99	51.745.949,21	35.137.993,84	31.423.159,47	21.394.606,00	14.878.604,38
<b>Total Sales</b>	<b>114.224.917,39</b>	<b>87.143.129,73</b>	<b>63.664.959,12</b>	<b>50.450.192,58</b>	<b>32.370.318,50</b>	<b>20.536.320,10</b>
Gross profit (on non-biological assets)	7.774.153,84	2.975.689,50	2.372.209,12	866.683,40	749.311,48	1.076.791,22
Impact from measurement biological assets on fair value	-2.978.929,17	1.485.108,47	14.102.092,70	17.823.578,83		
Cost of developing biological assets	-37.581.617,22	-38.761.678,15	-38.575.927,37	-29.134.419,21		
Gross Operating Profit	19.032.969,44	17.445.069,03	13.036.368,29	20.979.002,49		
Earnings before taxes, financial and investment results	5.191.945,42	7.906.258,99	6.980.235,57	13.342.902,25	5.497.816,09	3.486.865,43
Earnings before tax	727.638,12	4.004.673,30	3.114.343,17	11.556.028,66	5.237.083,04	2.898.995,50
Earnings net of tax	412.114,08	2.515.703,86	2.473.017,61	8.447.945,10	4.179.811,89	2.049.424,91
Allocated among:						
Company shareholders	412.114,08	2.515.703,86	2.473.017,61	8.447.945,10	4.179.811,89	2.049.424,91
Minority interest						
<b>Basic share of net earnings per share (in €)</b>	<b>0,0164</b>	<b>0,10</b>	<b>0,10</b>	<b>0,43</b>	<b>0,21</b>	<b>0,11</b>
<b>Dividend proposed per share (in €)</b>				<b>0,06</b>	<b>0,05</b>	<b>0,04</b>
<b>Earnings before taxes, financial and investment results and total depreciation</b>	<b>6.972.633,91</b>	<b>10.341.246,80</b>	<b>8.873.813,39</b>	<b>14.909.848,31</b>	<b>6.469.938,18</b>	<b>4.172.641,54</b>